Rallybio Announces Acceptance of Abstract for RLYB212 at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH)

Rhea-AI Summary

Rallybio Corporation (NASDAQ: RLYB) announced that an abstract for RLYB212, an anti-HPA-1a monoclonal antibody, was accepted for presentation at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Montreal from June 24-28. RLYB212 aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is focused on developing therapies for severe rare diseases and has a robust pipeline, including RLYB116, a C5 complement inhibitor. Investors are reminded of the risks associated with clinical trials, potential funding challenges, and competition in the biotechnology sector.

Positive

• RLYB212's acceptance for presentation at a significant international congress, potentially increasing visibility.
• Rallybio's focus on developing therapies for severe and rare diseases may attract investor interest.

Negative

• Risks related to the success of clinical trials for RLYB212 and funding challenges.
• Competition from other biotechnology and pharmaceutical companies may hinder progress.

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio Corporation (Nasdaq: RLYB) today announced that an abstract for RLYB212 reporting results from the Phase 1b proof-of-concept study has been accepted for presentation at the 31^st Congress of the International Society on Thrombosis and Haemostasis (ISTH), which will take place in Montreal from June 24-28. RLYB212 is an anti-HPA-1a monoclonal antibody being developed for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

Additional information about the ISTH 2023 Congress is available at: https://www.isth2023.org/.

About Rallybio

Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, a C5 complement inhibitor with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development.

Rallybio is headquartered in New Haven, Connecticut with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com and follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements that are based on our management’s beliefs and assumptions and on currently available information. All statements, other than statements of historical facts contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements concerning the expected progress, results and plans for RLYB212. The forward-looking statements in this press release are only predictions and are based largely on management’s current expectations and projections about future events and financial trends that management believes may affect Rallybio’s business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our ability to successfully initiate and conduct our planned clinical trials, including the FNAIT natural history study, and the Phase 1 and 1b clinical trials for RLYB212, and complete such clinical trials and obtain results on our expected timelines, or at all, whether our cash resources will be sufficient to fund our operating expenses and capital expenditure requirements and whether we will be successful raising additional capital, our ability to enter into strategic partnerships or other arrangements, competition from other biotechnology and pharmaceutical companies, and those risks and uncertainties described in Rallybio’s filings with the U.S. Securities and Exchange Commission (SEC), including Rallybio’s Annual Report on Form 10-K for the period ended December 31, 2022, and subsequent filings with the SEC. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we are not obligated to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events, changed circumstances or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230330005560/en/

Investor

Ami Bavishi

Head of Investor Relations and Communications

475-47-RALLY (Ext. 282)

abavishi@rallybio.com

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Media

Tara DiMilia

908-369-7168

Tara.dimilia@tmstrat.com

Source: Rallybio Corporation

FAQ

What is RLYB212 and its significance to Rallybio Corporation?

RLYB212 is an anti-HPA-1a monoclonal antibody being developed to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), marking a potential advancement in maternal-fetal health.

When and where is the 31st Congress of the ISTH taking place?

The 31st Congress of the International Society on Thrombosis and Haemostasis will be held in Montreal from June 24-28.

What are the main risks mentioned in Rallybio's recent press release?

The risks include the success of clinical trials for RLYB212 and potential funding challenges, along with competition from other companies.

How does RLYB fit into Rallybio's overall pipeline?

RLYB212 is part of Rallybio's broader pipeline targeting severe and rare diseases, alongside other products like RLYB116.